Skip to content

A clinical study of MK-1289 in healthy adult men (MK-1289-001)

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521395-63-00
Acronym
MK-1289-001
Enrollment
28
Registered
2025-06-02
Start date
2025-06-04
Completion date
2025-09-26
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Infection

Interventions

None listed

Sponsors

Merck Sharp & Dohme LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026